ArticleCureus2026
Evaluation of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients With Acute Heart Failure in the Emergency Department.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute heart failure is a common cause of emergency department admissions and is associated with high morbidity and mortality.
objectiveTo evaluate the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting severity and clinical outcomes in patients presenting with acute heart failure in the emergency department.
methodsThis cross-sectional analytical study was conducted at the Department of Cardiology, Punjab Institute of Cardiology, Lahore, Pakistan from January 2025 to July 2025, on 225 patients diagnosed with acute heart failure. NT-proBNP levels were measured at admission. Patients were followed during hospital stay for outcomes including severity of heart failure, need for ICU admission, duration of hospital stay, complications, and in-hospital mortality.
resultsThe mean NT-proBNP level was significantly higher in patients with severe heart failure compared to mild to moderate cases (6,920 ± 2,310 pg/mL vs 3,240 ± 1,580 pg/mL, p < 0.001). Patients requiring ICU admission and those with complications or mortality had markedly elevated NT-proBNP levels (p < 0.001). A significant positive correlation was observed between NT-proBNP levels and duration of hospital stay (r = 0.52, p < 0.001). Receiver operating characteristic curve analysis showed good predictive accuracy for severe acute heart failure, with an area under the curve of 0.86 (95% CI: 0.80-0.91; p<0.001). The optimal NT-proBNP cutoff value of 5000 pg/mL was determined using the Youden Index, yielding a sensitivity of 82.1% and specificity of 76.4%.
conclusionNT-proBNP is a reliable prognostic marker in acute heart failure, strongly associated with disease severity, adverse outcomes, and prolonged hospitalization. Its use in the emergency department can facilitate early risk stratification and guide clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.